Page last updated: 2024-11-04

vorinostat and HIV Coinfection

vorinostat has been researched along with HIV Coinfection in 53 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Research Excerpts

ExcerptRelevanceReference
"Tamoxifen did not enhance vorinostat-induced HIV transcription (between-arm ratio, 0."3.11Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial. ( Aga, E; Archin, N; Bosch, RJ; Chomont, N; Connick, E; Coxen, K; Deeks, S; Dobrowolski, C; Ehui, L; Gandhi, M; Gandhi, RT; Giguel, F; Godfrey, C; Hosey, L; Howell, BJ; Karn, J; Kuritzkes, DR; Ma, Q; Morse, GD; Scully, EP; Sieg, SF; Squires, KE; Starr, K; Tsibris, A; Wu, G, 2022)
"Vorinostat was safe and well tolerated and there were no dose modifications or study drug discontinuations."2.79Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. ( Ahlers, J; Brown, G; Cameron, MJ; Cameron, PU; Chomont, N; Deeks, SG; Elliott, JH; Fromentin, R; Ghneim, K; Hazuda, DJ; Hoy, JF; Johnstone, RW; Lewin, SR; Martin, BP; McMahon, J; Odevall, L; Palmer, S; Prince, MH; Procopio, FA; Roney, J; Sékaly, RP; Sinclair, E; Smith, MZ; Solomon, A; Spelman, T; Velayudham, P; Watson, J; Wightman, F; Zeidan, J, 2014)
"The combination of prolonged high-dose disulfiram and vorinostat was not safe in PWH on ART and should not be pursued despite evidence of latency reversal."1.72Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal. ( Blennow, K; Bumpus, N; Burger, D; Chang, J; Dantanarayana, A; Evans, VA; Fisher, K; Gisslen, M; Hagenauer, M; Heck, CJS; Howell, BJ; Lau, JSY; Lee, S; Lewin, SR; McMahon, JH; Palmer, S; Rasmussen, TA; Solomon, A; Symons, J; Tennakoon, S; Wu, G; Zerbato, JM; Zetterberg, HH; Zuck, P, 2022)
"Soraphen A is a myxobacterial metabolite that blocks the acetyl-coenzyme A carboxylase of the host and was previously identified as a novel HIV inhibitor."1.46The Myxobacterial Metabolite Soraphen A Inhibits HIV-1 by Reducing Virus Production and Altering Virion Composition. ( Bosch, M; Brönstrup, M; Diez, J; Fleta-Soriano, E; Lopez-Iglesias, C; Lorca Oró, C; Martínez, JP; Meyerhans, A; Mirambeau, G; Pol, A; Sadiq, SK; Smutná, K, 2017)
" We sought to identify the optimal dosing of VOR for effective serial reversal of HIV latency."1.46Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency. ( Allard, B; Archin, NM; Clutton, G; Eron, J; Gay, CL; Goonetilleke, N; Kashuba, AD; Kirchherr, JL; Kuruc, JD; Margolis, DM; Sholtis, K; Stuelke, E; Sung, JA; Xu, Y, 2017)
"We recorded a total of 31 adverse events (26 grade 1 and five grade 2) in all study participants (n = 20)."1.46No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy. ( Dantanarayana, A; Elliott, JH; Hagenauer, M; Hoy, JF; Lewin, SR; McMahon, J; Mota, TM; Prince, HM; Purcell, DFJ; Rasmussen, TA; Rhodes, A; Roney, J; Spelman, T; Tennakoon, S; Wightman, F, 2017)
"Vorinostat does not enhance viral fusion with cells but rather enhances the kinetics and efficiency of postentry viral events, including reverse transcription, nuclear import, and integration, and enhances viral production in a spreading-infection assay."1.40The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events. ( Dobrowolski, C; Haqqani, AA; Karn, J; Lucera, MB; Mao, H; Tabler, CO; Tilton, CA; Tilton, JC, 2014)

Research

Studies (53)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (3.77)29.6817
2010's36 (67.92)24.3611
2020's15 (28.30)2.80

Authors

AuthorsStudies
Mejia, EJ1
Loveridge, ST1
Stepan, G1
Tsai, A1
Jones, GS1
Barnes, T1
White, KN1
Drašković, M1
Tenney, K1
Tsiang, M1
Geleziunas, R1
Cihlar, T1
Pagratis, N1
Tian, Y1
Yu, H1
Crews, P1
Lopes, JR1
Chiba, DE1
Dos Santos, JL1
Gay, CL5
James, KS2
Tuyishime, M2
Falcinelli, SD3
Joseph, SB1
Moeser, MJ1
Allard, B4
Kirchherr, JL3
Clohosey, M1
Raines, SLM1
Montefiori, DC1
Shen, X1
Gorelick, RJ2
Gama, L1
McDermott, AB1
Koup, RA1
Mascola, JR1
Floris-Moore, M1
Kuruc, JD6
Ferrari, G2
Eron, JJ3
Archin, NM10
Margolis, DM13
McMahon, JH2
Evans, VA1
Lau, JSY1
Symons, J1
Zerbato, JM2
Chang, J1
Solomon, A3
Tennakoon, S2
Dantanarayana, A3
Hagenauer, M3
Lee, S1
Palmer, S3
Fisher, K1
Bumpus, N1
Heck, CJS1
Burger, D1
Wu, G4
Zuck, P1
Howell, BJ3
Zetterberg, HH1
Blennow, K1
Gisslen, M1
Rasmussen, TA5
Lewin, SR11
Scully, EP1
Aga, E1
Tsibris, A1
Archin, N3
Starr, K2
Ma, Q1
Morse, GD1
Squires, KE1
Hosey, L2
Sieg, SF1
Ehui, L1
Giguel, F1
Coxen, K1
Dobrowolski, C2
Gandhi, M1
Deeks, S1
Chomont, N2
Connick, E1
Godfrey, C2
Karn, J2
Kuritzkes, DR2
Bosch, RJ3
Gandhi, RT1
Day, S1
Mathews, A1
Blumberg, M1
Vu, T1
Rennie, S1
Tucker, JD1
Fidler, S1
Stöhr, W1
Pace, M1
Dorrell, L1
Lever, A1
Pett, S1
Kinloch-de Loes, S1
Fox, J1
Clarke, A1
Nelson, M1
Thornhill, J1
Khan, M1
Fun, A1
Bandara, M1
Kelly, D1
Kopycinski, J1
Hanke, T1
Yang, H1
Bennett, R1
Johnson, M1
Howell, B1
Barnard, R2
Kaye, S1
Wills, M1
Babiker, A1
Frater, J2
Dubé, K1
Barr, L1
Evans, D1
Hoffman, E1
Campbell, DM1
Simoni, J1
Sugarman, J1
Sauceda, J1
Brown, B1
Diepstra, KL1
Wohl, DA1
Gandhi, R1
Scully, E1
Warren, JA1
Reifeis, SA1
Dewey, MG1
Helms, A1
Stuelke, E2
Gamble, A1
Plachco, A1
Hudgens, M1
Garrido, C4
Goonetilleke, N3
DeBenedette, MA1
Tcherepanova, IY1
Nicolette, CA1
De la Torre-Tarazona, HE1
Jiménez, R1
Bueno, P1
Camarero, S1
Román, L1
Fernández-García, JL1
Beltrán, M1
Nothias, LF1
Cachet, X1
Paolini, J1
Litaudon, M1
Alcami, J1
Bedoya, LM1
Maxwell, JW1
Nefedov, A1
Dorfmeier, C1
Dewey, M1
Webber, AL1
Hazuda, DJ3
Barnard, RJO1
Ramos, JC1
Sparano, JA1
Chadburn, A1
Reid, EG1
Ambinder, RF1
Siegel, ER1
Moore, PC1
Rubinstein, PG1
Durand, CM2
Cesarman, E1
Aboulafia, D1
Baiocchi, R1
Ratner, L1
Kaplan, L1
Capoferri, AA1
Lee, JY1
Mitsuyasu, R1
Noy, A1
Piekna-Przybylska, D1
Bambara, RA1
Maggirwar, SB1
Dewhurst, S1
Witzig, TE1
Feng, Z1
Yang, Z1
Gao, X1
Xue, Y1
Wang, X1
Khoury, G2
Zhao, W1
Gartner, MJ1
Pascoe, RD1
Rhodes, A2
Gooey, M1
Anderson, J2
Bacchetti, P1
Deeks, SG4
McMahon, J4
Roche, M1
Purcell, DF1
Fleta-Soriano, E1
Smutná, K1
Martínez, JP1
Lorca Oró, C1
Sadiq, SK1
Mirambeau, G1
Lopez-Iglesias, C1
Bosch, M1
Pol, A1
Brönstrup, M1
Diez, J1
Meyerhans, A1
Desimio, MG1
Giuliani, E1
Doria, M1
Sung, JA3
Clutton, G2
Sholtis, K2
Xu, Y2
Kashuba, AD2
Eron, J1
Kirchherr, J2
Nordstrom, JL1
Bollard, CM2
Kim, Y1
Anderson, JL1
Jiang, G1
Nguyen, D1
Yukl, SA2
Méndez-Lagares, G1
Tang, Y1
Elsheikh, MM1
Thompson, GR1
Hartigan-O'Connor, DJ1
Wong, JK2
Dandekar, S1
Abad-Fernandez, M1
Pollara, JJ1
Soriano-Sarabia, N2
White, CH1
Beliakova-Bethell, N1
Lada, SM1
Breen, MS1
Hurst, TP1
Spina, CA2
Richman, DD2
Magiorkinis, G1
Woelk, CH1
Andersen, RJ1
Ntie-Kang, F1
Tietjen, I1
Chandra, PK1
Gerlach, SL1
Wu, C1
Khurana, N1
Swientoniewski, LT1
Abdel-Mageed, AB1
Li, J1
Braun, SE1
Mondal, D1
Tolstrup, M2
Søgaard, OS2
Kent, SJ1
Reece, JC1
Petravic, J1
Martyushev, A1
Kramski, M1
De Rose, R1
Cooper, DA1
Kelleher, AD1
Emery, S1
Cameron, PU3
Davenport, MP1
Bosque, A1
Chan, J1
Famiglietti, M1
Greene, WC2
Kashuba, A2
Mau, M1
Ruelas, D1
Saleh, S1
Shirakawa, K1
Siliciano, RF3
Singhania, A1
Soto, PC1
Terry, VH1
Verdin, E1
Woelk, C1
Wooden, S1
Xing, S1
Planelles, V1
Doyon, G1
Sobolewski, MD2
Huber, K1
McMahon, D1
Mellors, JW2
Sluis-Cremer, N1
Ramakrishnan, R1
Liu, H1
Rice, AP2
Klase, Z1
Yedavalli, VS1
Houzet, L1
Perkins, M1
Maldarelli, F1
Brenchley, J1
Strebel, K1
Liu, P1
Jeang, KT1
Bullen, CK1
Laird, GM2
Siliciano, JD1
Cillo, AR1
Fyne, E1
Piatak, M1
Coffin, JM2
Ho, YC1
Lucera, MB1
Tilton, CA1
Mao, H1
Tabler, CO1
Haqqani, AA1
Tilton, JC1
Halper-Stromberg, A1
Lu, CL1
Klein, F1
Horwitz, JA1
Bournazos, S1
Nogueira, L1
Eisenreich, TR1
Liu, C1
Gazumyan, A1
Schaefer, U1
Furze, RC1
Seaman, MS1
Prinjha, R1
Tarakhovsky, A1
Ravetch, JV1
Nussenzweig, MC1
Elliott, JH3
Wightman, F4
Ghneim, K1
Ahlers, J1
Cameron, MJ1
Smith, MZ1
Spelman, T2
Velayudham, P1
Brown, G1
Roney, J3
Watson, J1
Prince, MH1
Hoy, JF2
Fromentin, R1
Procopio, FA1
Zeidan, J1
Odevall, L1
Johnstone, RW1
Martin, BP1
Sinclair, E1
Sékaly, RP1
Lu, HK1
Gray, LR1
Ellenberg, P2
Cheng, WJ1
Mota, TM2
Wesselingh, S1
Gorry, PR1
Churchill, MJ1
Lam, S1
Rooney, CM1
Jamaluddin, MS1
Hu, PW1
Jan, Y1
Siwak, EB1
Perdigão, P1
Gaj, T1
Santa-Marta, M1
Barbas, CF1
Goncalves, J1
Li, P1
Kaiser, P1
Lampiris, HW1
Kim, P1
Havlir, DV1
Baldoni, PL1
Mollan, KR1
Newhard, W1
Cox, K1
Hudgens, MG2
Barton, K1
Hiener, B1
Winckelmann, A1
Shao, W1
Byth, K1
Lanfear, R1
Harrington, S1
Buzon, M1
Lichterfeld, M1
Denton, PW1
Olesen, R1
Østergaard, L1
Purcell, DFJ1
Prince, HM1
Contreras, X1
Schweneker, M1
Chen, CS1
McCune, JM1
Martin, J1
Peterlin, BM1
Espeseth, A1
Parker, D1
Cheema, M1
Hazuda, D1
Churchill, M1
Friedrich, MJ1
Liberty, AL1
Choudhary, SK1
Crooks, AM1
Parker, DC1
Anderson, EM1
Kearney, MF1
Strain, MC1

Clinical Trials (15)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
IGHID 11802 - Combination Therapy With the Novel Clearance Modality (VRC07-523LS) and the Latency Reversal Agent (Vorinostat) to Reduce the Frequency of Latent, Resting CD4+ T Cell Infection (The VOR-07 Study)[NCT03803605]Phase 115 participants (Actual)Interventional2019-02-12Completed
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors[NCT03382834]Phase 231 participants (Actual)Interventional2018-04-26Active, not recruiting
Research In Viral Eradication of HIV Reservoirs[NCT02336074]Phase 260 participants (Actual)Interventional2015-11-27Completed
A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma[NCT01193842]Phase 1/Phase 2107 participants (Actual)Interventional2010-10-06Completed
A Phase I/II Investigation of the Effect of Vorinostat (VOR) on HIV RNA Expression in the Resting CD4+ T Cells of HIV-Infected Patients Receiving Stable Antiretroviral Therapy[NCT01319383]Phase 1/Phase 225 participants (Actual)Interventional2011-02-28Completed
The Safety and Efficacy of The Histone Deacetylase Inhibitor Panobinostat for Purging HIV-1 From The Latent Reservoir (CLEAR) Study[NCT01680094]Phase 1/Phase 215 participants (Actual)Interventional2012-09-30Completed
IGHID 11424 - A Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (The VOR VAX Study)[NCT02707900]Phase 16 participants (Actual)Interventional2016-03-31Terminated (stopped due to Manufacturing of the AGS-004 HIV vaccine by Argos could no longer be provided.)
Investigation of the Impact of Inducible, Replication-competent Latent HIV-1 as an Impediment to HIV/AIDS Cure in the Context of Sustained Viral Suppression[NCT04938518]222 participants (Anticipated)Observational [Patient Registry]2019-05-01Recruiting
Evaluation of the Efficacy and Mechanisms of a Novel Intervention for Chronic Pain Tailored to People Living With HIV[NCT03692611]280 participants (Actual)Interventional2019-08-14Active, not recruiting
A Randomized Study to Compare the Efficacy of Vorinostat/Hydroxychloroquine/Maraviroc (VHM) in Controlling HIV After Treatment Interruption in Subjects Who Initiated ART During Acute HIV Infection[NCT02475915]Phase 1/Phase 215 participants (Actual)Interventional2015-01-31Completed
A Pilot Study to Assess the Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral Therapy[NCT01365065]Phase 220 participants (Actual)Interventional2011-05-31Active, not recruiting
Quantitative Measurement and Correlates of the Latent HIV Reservoir in Virally Suppressed Ugandans[NCT02154035]90 participants (Actual)Observational2014-05-31Completed
IGHID 1309 -A Phase I Study to Evaluate the Kinetics of the Immunologic Response and Virologic Impact of AGS-004 in HIV-Infected Individuals Suppressed on Antiretroviral Therapy Initiated During Acute and Chronic HIV Infection[NCT02042248]Phase 16 participants (Actual)Interventional2014-03-31Completed
Simultaneous Disruption of Latency and Immune Enhancement by Poly-ICLC During HIV-1 Infection[NCT02071095]Phase 1/Phase 215 participants (Actual)Interventional2014-04-30Completed
IGHID 1320 - A Phase I Study to Evaluate the Safety, Immunologic, and Virologic Responses of HIV-1 Antigen Expanded Specific T Cell Therapy (HXTC) as a Therapeutic Strategy in HIV-Infected Individuals Started on Antiretroviral Therapy During Acute and Chr[NCT02208167]Phase 16 participants (Actual)Interventional2015-04-07Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Percent of Participants With a Grade 3 or Higher Treatment-Related Adverse Event (AE)

The DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017 was used to measure safety where Grade 3 is defined as severe and Grade 4 is defined as potentially life-threatening. Treatment-Related AEs assessments are considered related to study product as possible, probable, or definite as defined in the protocol. (NCT03803605)
Timeframe: First day of study treatment through end of study, a total of approximately 36 weeks

Interventionpercentage of participants (Number)
VRC07-523LS + Vorinostat (VOR)0

Change From Baseline in Cell-associated HIV-1 RNA in CD4+ T Cells

Baseline is defined as the average of the pre-entry and entry values. Change was calculated as the value of Cell-associated HIV-1 RNA on Day 38 (5 hours post vorinostat) minus the value at baseline. (NCT03382834)
Timeframe: Pre-entry, entry, and Day 38

Interventionlog10 copies/million CD4 cells (Mean)
Arm A: Tamoxifen + Vorinostat0.06
Arm B: Vorinostat Alone0.17

Change From Baseline in Total HIV-1 DNA Levels in CD4+ T Cells

Baseline is defined as the average of the pre-entry and entry values. Change was calculated as the value of Total HIV-1 DNA on Day 38 (5 hours post vorinostat) minus the value at baseline. (NCT03382834)
Timeframe: Pre-entry, entry, and Day 38

Interventionlog10 copies/million CD4 cells (Mean)
Arm A: Tamoxifen + Vorinostat0
Arm B: Vorinostat Alone-0.04

Proportion of Participants With New Grade 3 or Greater Adverse Events

Proportion of participants with new Grade 3 or greater adverse events that are considered definitely, probably, or possibly related to study treatment (as judged by the core protocol team). The DAIDS AE Grading Table (corrected Version 2.1, July 2017) was used. (NCT03382834)
Timeframe: Measured from study entry through Day 65

Interventionproportion of participants (Number)
Arm A: Tamoxifen + Vorinostat0
Arm B: Vorinostat Alone0

Number of Participants With HIV-1 RNA Levels (Measured by Single Copy Assay) Greater or Equal to the Lower Limit of Quantification

Number of participants with HIV-1 RNA levels measured by single copy assay (SCA) greater or equal to the lower limit of quantification (LOQ). The lower limit of quantification for this study was 0.47 copies/mL. (NCT03382834)
Timeframe: Pre-entry, entry, Day 28, Day 35, Day 38 (5 hours post vorinostat), Day 45, Day 65

,
InterventionParticipants (Count of Participants)
Pre-entry SCA >= LOQEntry SCA >=LOQDay 28 SCA >=LOQDay 35 SCA >=LOQDay 38 SCA >=LOQDay 45 SCA >=LOQDay 65 SCA >=LOQ
Arm A: Tamoxifen + Vorinostat10911117910
Arm B: Vorinostat Alone6345545

Histone H4 Acetylation

Histone H4 acetylation using a H4K5/8/12/16 immunoassay with thawed PBMC derived cell lysates added to an ELISA using anti-H4 monoclonal antibody (NCT02336074)
Timeframe: 12 weeks

InterventionFold increase pre to post vorinostat (Mean)
Intervention (Arm B - ART + Vaccines + Vorinostat)3.19

Quantitative Viral Outgrowth

Number of Participants with undetectable quantitative viral outgrowth (NCT02336074)
Timeframe: At week 16

InterventionParticipants with undetectable outgrowth (Number)
Control (Arm A - ART Only)12
Intervention (Arm B - ART + Vaccines + Vorinostat)6

Total HIV DNA From CD4 T-cells

The average of two measures taken at post-randomisation week 16 and 18 (NCT02336074)
Timeframe: Averaged across post-randomisation week 16 and 18

InterventionHIV-DNA copies/mill CD4+ T cells (log10) (Mean)
Control (Arm A - ART Only)2.95
Intervention (Arm B - ART + Vaccines + Vorinostat)3.06

Viral Inhibition

"CD8+ T cell antiviral suppressive activity was expressed as percentage elimination and determined as follows: [(fraction of p24+ cells in CD4+ T cells cultured alone) - (fraction of p24 + in CD4+ T cells cultured with CD8+ cells)]/(fraction of p24+ cells in CD4+ T cells cultured alone) × 100.~Viral inhibition Assay" (NCT02336074)
Timeframe: 12 weeks

InterventionPercentage elimination (Mean)
Control (Arm A - ART Only)-18.25
Intervention (Arm B - ART + Vaccines + Vorinostat)1.50

CD8+ T-cell Responses

Percentage of CD8+ CD107a+ IFNγ+ T cells , assessed using an optimized and qualified flow cytometry panel. (NCT02336074)
Timeframe: 12 weeks

,
Intervention% cells CD8+ CD107a+ IFNγ+ (Median)
Post randomisation week 9Post randomisation week 12
Control (Arm A - ART Only)0.0520.062
Intervention (Arm B - ART + Vaccines + Vorinostat)0.1940.263

Percentage of CD4+ CD154+ IFNγ+ T Cells

Percentage of CD4+ CD154+ IFNγ+ T cells , assessed using an optimized and qualified flow cytometry panel. (NCT02336074)
Timeframe: 12 weeks

,
Intervention% cells CD4+ CD154+ IFNγ+ (Median)
Post randomisation week 9Post randomisation week 12
Control (Arm A - ART Only)0.0060.006
Intervention (Arm B - ART + Vaccines + Vorinostat)0.0970.109

Event-free Survival (EFS) (Phase II)

The percentage of participants surviving without events (relapse or death) one year after starting treatment. (NCT01193842)
Timeframe: 1 year

Interventionpercentage of participants (Number)
Phase II: VR-DA-EPOCH75.6
Phase II: DA-R-EPOCH82.2

Overall Survival (OS) (Phase II)

The percentage of participants surviving one year after starting treatment. (NCT01193842)
Timeframe: 1 year

Interventionpercentage of participants (Number)
Phase II: VR-DA-EPOCH77.6
Phase II: DA-R-EPOCH86.7

Percentage of Participants With Complete Response (CR) as Assessed by Response Evaluation Criteria in Solid Tumors (Phase II)

"Percentage of participants with complete response as assessed by Response Evaluation Criteria in Solid Tumors (Phase II) according to treatment arm. Participants are planned to be treated for a total of 6 cycles (21 day cycle length). Participants with CR after Cycle 4 will receive two additional cycles of chemotherapy and complete 6 cycles of chemotherapy. Participants who achieve a partial response (PR) only after Cycle 4 may continue on protocol therapy or they may be removed from the study at the AMC discretion of the physician (local Principal Investigator). Participants with stable disease after 4 cycles (i.e., who did not achieve at least a PR) or progressive disease at any time will be removed from study.~In phase II, there are two arms: Vorinostat RPTD+rituximab-DA-EPOCH arm (VR-DA-EPOCH) and Rituximab-DA-EPOCH arm (DA-R-EPOCH)." (NCT01193842)
Timeframe: Up to 6 months

Interventionpercentage of participants (Number)
Phase II: VR-DA-EPOCH67.5
Phase II: DA-R-EPOCH76.2

Recommended Phase II Dose of Vorinostat Determined According to Dose-limiting Toxicities Graded Using Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase I)

Recommended phase II dose of vorinostat is defined as the dose level at which 0/6 or 1/6 subjects experience dose limiting toxicity (DLT) with the next higher dose having at least 2/3 or 2/6 subjects encountering DLT (Phase I). Toxicities will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Using a 3+3 design, the recommended phase II dose is defined as the level at which 0/6 or 1/6 patients experiences at dose-limiting toxicity in the first cycle. (NCT01193842)
Timeframe: 21 days

InterventionMg per day of Vorinostat (Number)
Phase I: VR-DA-EPOCH300

Change in CD8 Cell Counts (Phase I)

Differences from baseline (specified follow-up assessment minus baseline) in absolute CD8 counts. (NCT01193842)
Timeframe: Baseline up to 12 months

,,
Interventioncells/mm^3 (Median)
End of cycle 2Treatment discontinuation6-month follow-up12-month follow-up
Phase I: VR-CHOP, Dose Level 1-172-81-16128
Phase I: VR-DA-EPOCH, Dose Level 135.5-164.5-56604
Phase I: VR-DA-EPOCH, Dose Level 2-115211275154

Change in Plasma Associated Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (Phase I)

Differences from baseline (specified follow-up assessment minus baseline) in HIV viral load. Undetectable viral load results were treated as 0 values. (NCT01193842)
Timeframe: Baseline up to 12 months

,,
Interventioncopies per milliliter (Median)
End of cycle 2Treatment discontinuation6-month follow-up12-month follow-up
Phase I: VR-CHOP, Dose Level 128000
Phase I: VR-DA-EPOCH, Dose Level 1-14518-4517-551160
Phase I: VR-DA-EPOCH, Dose Level 2-12.5000

Changes in Absolute CD4 Cell Counts (Phase I)

Differences from baseline (specified follow-up assessment minus baseline) in absolute CD4 counts. (NCT01193842)
Timeframe: Baseline up to 12 months

,,
Interventioncell/mm^3 (Median)
End of cycle 2Treatment discontinuation6-month follow-up12-month follow-up
Phase I: VR-CHOP, Dose Level 1-218-190-175-84
Phase I: VR-DA-EPOCH, Dose Level 192-3976169
Phase I: VR-DA-EPOCH, Dose Level 2-9-293131

Changes in Epstein-Barr Virus (EBV) Viral Load

Differences from baseline (specified follow-up assessment minus baseline) in EBV viral load. (NCT01193842)
Timeframe: Baseline up to 12 months

,,,
InterventionIU/mL (Median)
End of Cycle 2At treatment discontinuation6-month follow-up12-month follow-up
Phase I: VR-DA-EPOCH, Dose Level 10000
Phase I: VR-DA-EPOCH, Dose Level 2-2436.1-1.92-1.92-1.15
Phase II, DA-R-EPOCH0-0.280-2.7
Phase II, VR-DA-EPOCH-0.61-2.9-1.55-0.56

Changes in Human Herpes Virus (HHV)-8 Viral Load

Differences from baseline (specified follow-up assessment minus baseline) in (HHV)-8 viral load. (NCT01193842)
Timeframe: Baseline up to 12 months

Interventioncopies per 100uL (Median)
12-month follow-up
Phase II: VR-DA-EPOCH0

Changes in Human Herpes Virus (HHV)-8 Viral Load

Differences from baseline (specified follow-up assessment minus baseline) in (HHV)-8 viral load. (NCT01193842)
Timeframe: Baseline up to 12 months

Interventioncopies per 100uL (Median)
At treatment discontinuation6-month follow-up12-month follow-up
Phase II: DA-R-EPOCH000

Changes in Human Immunodeficiency Virus (HIV) Viral Load

Differences from baseline (specified follow-up assessment minus baseline) in HIV viral load. Undetectable viral load results were treated as 0 values. (NCT01193842)
Timeframe: Baseline up to 12 months

,
Interventionmedian change in copies per mL (Median)
End of Cycle 2At treatment discontinuation6-month follow-up12-month follow-up
Phase II: DA-R-EPOCH-25-22.5-18-20
Phase II: VR-DA-EPOCH-20-87-200

Percentage of Participant Experiencing Adverse Events (AEs) for Each Treatment Arm as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase II)

The percentage of participants with AEs and their worst severity will be tabulated for each treatment arm. If a participant has more than one AE, the most severe AE is analyzed. All adverse events will be assessed by the investigator from the first dose of protocol therapy through the post-treatment discontinuation visit. Participants are planned to be treated for a total of 6 cycles (21 day cycle length), or roughly 4 months. After this evaluation, assessment and reporting of AEs will only be required for all grade 5 AEs and any serious AE (SAE) that the investigator considers related to protocol therapy. (NCT01193842)
Timeframe: Up to 5 years

,
Interventionpercentage of participants (Number)
DeathLife-threateningSevereModerateMild
Phase II: DA-R-EPOCH20.028.931.117.80
Phase II: VR-DA-EPOCH28.937.820.08.92.2

Pharmacokinetic Clearance (Phase I)

Serial plasma samples for pharmacokinetic analysis were collected at 24-48, 48-72, and 72-96 hours after the start of the first chemotherapy infusion. Doxorubicin, etoposide, and vincristine concentrations were determined using a validated liquid chromatography-tandem mass spectrometry method. The clearance was determined by dividing the drug-infusion rate by the steady-state concentrations, which was the average of the three time points. (NCT01193842)
Timeframe: 24-48, 48-72, and 72-96 hours after the start of the first chemotherapy infusion

,
InterventionLiter/hour (Mean)
DoxorubicinEtoposideVincristine
Phase I: VR-DA-EPOCH, Dose Level 178.63.022.4
Phase I: VR-DA-EPOCH, Dose Level 276.02.416.8

Tumor Response (Phase I)

The percentage of participants whose best tumor response is complete response (CR) or partial response (PR). Based on clinical, radiologic (CT), and pathologic criteria, CR requires 1) complete disappearance of all detectable disease and disease-related symptoms if present before therapy, 2) bone marrow aspirate and biopsy to confirm a CR if initially positive or if clinically indicated by new abnormalities in the peripheral blood counts or blood smear, 3) negative PET results, depending on typically, variably, or unknown pre-treatment FDG status, and 4) spleen and/or liver, if considered to be enlarged before therapy on physical examination or CT scan, not being palpable on physical examination and considered normal size by imaging studies, and nodules related to lymphoma disappeared. PR includes 1) ≥50% decrease in sum of product of diameters (SPD), 2) no increase in size of nodes, liver, or spleen, 3) splenic/hepatic nodules regressed by ≥ 50% SPD, 4) no new sites of disease (NCT01193842)
Timeframe: Up to 2 years post treatment

,,
Interventionpercentage of participants (Number)
Complete responsePartial Response
Phase I: Arm C (VR-CHOP) Dose Level 11000
Phase I: VR-DA-EPOCH, Dose Level 183.316.7
Phase I: VR-DA-EPOCH, Dose Level 283.316.7

Number of Participants Developing Cancer Within 5 Years Following >/= 8 Vorinostat Dose Exposures

Development of a new cancer within the 5 years of taking their last dose of VOR 400 mg PO.All participants receiving one or more doses of VOR 400 mg PO in any and all Arms of the study. Pre-specified to be reported as one group. (NCT01319383)
Timeframe: From last dose Vorinostat to 5 years afterwards

InterventionParticipants (Count of Participants)
1/Single and Multiple Dose, Step 30
2/Interval Doses (Multiple) Step 40

Number of Participants Exhibiting an in Vivo Resting CD4+ T Cell- Associated HIV RNA (RCVL) Increase After Receiving a Single Dose of VOR 400 mg PO

Participants in Arm 1 and 2 were analyzed in Step 2 for an in vivo increase in resting CD4+ T cell- associated HIV RNA (RCVL) after administration of a single dose of VOR 400 mg PO (NCT01319383)
Timeframe: Arm1: Baseline, Visit 5 and Arm 2: Baseline and Visit 3

InterventionParticipants (Count of Participants)
1/Single & Multiple Dose, Step 2, Visit 58
2/Interval Dosing, Visit 34

Number of Participants Exhibiting an in Vivo Resting CD4+ T-cell-associated HIV RNA (Rc-RNA) Increase Following Each of Two Multiple Dose Cycles (11 Doses/Cycle)

Participants in Arm 1, Step 3 were analyzed for an in vivo increase in the resting CD4+ T cell- associated HIV RNA (RCVL) after 11 doses of VOR 400 mg PO. This cycle was repeated after a 5 - 8 week rest period for a 2nd series and measurement. (NCT01319383)
Timeframe: Baseline, Visit 18, Visit 29

InterventionParticipants (Count of Participants)
Arm 1 - Single and Multiple Dose, Step 30

Number of Participants Exhibiting an in Vivo Resting CD4+ T-cell-associated HIV RNA (Rc-RNA) Increase Following Multiple (n = 10) Interval Doses

Participants in Arm 2, Step 4 were analyzed for an in vivo increase in the resting CD4+ T cell- associated HIV RNA (RCVL) after administration of 10 doses of VOR 400 mg PO, given 72 hours apart. (NCT01319383)
Timeframe: Baseline, Visit 9

InterventionParticipants (Count of Participants)
Interval Doses (Multiple) Step 43

Number of Participants With a Significant in Vivo Response in Resting Cell Infection (RCI) and HIV RNA After Paired Doses

Induction of significant in vivo RCI and RCLV response after 2 doses of VOR 400 mg PO administered 48 hours apart or 72 hours apart (NCT01319383)
Timeframe: Baseline, Visit 6

InterventionParticipants (Count of Participants)
Interval Dosing , Step 3 (48 hr Interval)0
Interval Dosing, Step 3 (72 Hour Interval)6

Number of Participants With Confirmed Hematologic Toxicity >/= Grade 2 and Related to VOR Per Division of AIDS (DAIDS) Grading Table

DAIDS Grading Table- Grade 1- mild, Grade 2- moderate; Grade 3- severe Grade 4- potentially life-threatening. Pre specified to combine all participants into one arm. (NCT01319383)
Timeframe: 24 hrs following single dose and 1 week after last of multiple dose sequence

InterventionParticipants (Count of Participants)
1/Single & Multiple Dose, Steps 2 and 30
2/Interval Dosing, Steps 2, 3 and 40

Number of Participants With Confirmed Non-hematologic Toxicity >/= Grade 3 and Related to VOR Per Division of AIDS (DAIDS) Grading Table

DAIDS Grading Table- Grade 1- mild, Grade 2- moderate; Grade 3- severe Grade 4- potentially life-threatening. Pre specified to combine all participants into one arm. (NCT01319383)
Timeframe: 24 hrs following single dose and 1 week after last of multiple dose sequence

InterventionParticipants (Count of Participants)
1/Single & Multiple Dose, Steps 2 and 30
2/Interval Dosing, Steps 2, 3 and 40

Number of Participants With Measurable Changes in Plasma HIV-1 RNA

Assess for detectible HIV-1 RNA > 150 copies/mL, confirmed by repeat evaluation, following VOR dose. By standard assay and single copy assay. Pre specified to combine all participants into one arm. (NCT01319383)
Timeframe: 1 week after last VOR dose

InterventionParticipants (Count of Participants)
1/Single & Multiple Dose, Steps 2 and 30
2/Interval Dosing, Steps 2, 3 and 40

CD8 CD38 (Mean of Fluorescence)

the CD38-activation marker on CD8 T-cells (CD8/CD38). (NCT02071095)
Timeframe: Day 8

Interventionmean fluorescent intensity (MFI) (Mean)
Arm A: Poly-ICLC8.69
Arm B: Normal Saline2.35

NK Cell Number

Natural killer cells or NK cells are part of the innate immune defense against infection and cancer. (NCT02071095)
Timeframe: at 48 weeks

Interventioncells/µL (Mean)
Arm A: Poly-ICLC20.68
Arm B: Normal Saline19.41

Number Participants With Adverse Events

Safety measured by number of participants with adverse events. (NCT02071095)
Timeframe: Up to 48 weeks

InterventionParticipants (Count of Participants)
Arm A: Poly-ICLC11
Arm B: Normal Saline3

Percent Change in CD4+ Tcell-associated HIV-1 RNA as Compared to Baseline

CD4+ Tcell-associated HIV-1 RNA to determine whether Poly-ICLC disrupts viral latency in HIV-1-infected individuals on anti-retroviral therapy.Viral transcription assessed by monitoring cell associated HIV-1 RNA. Percent change compared to baseline. (NCT02071095)
Timeframe: Baseline, Day 2, Day 4, Day 8, Day 28

,
Interventionpercent change (Mean)
Day 2Day 4Day 8Day 28
Arm A: Poly-ICLC102.8134.8161.0199.6
Arm B: Normal Saline186.3254.766.33126.7

Plasma Interferon-gamma-inducible Protein-10 (IP-10) Level

One of the biomarkers of cellular immune activation and exhaustion quantified by flow cytometry. Normal range is 7.8-500 pg/ml. (NCT02071095)
Timeframe: Day 2 and Day 4

,
Interventionpg/ml (Mean)
Day 2Day 4
Arm A: Poly-ICLC381.43450.51
Arm B: Normal Saline100.65139.39

Reviews

5 reviews available for vorinostat and HIV Coinfection

ArticleYear
HIV latency reversal agents: A potential path for functional cure?
    European journal of medicinal chemistry, 2021, Mar-05, Volume: 213

    Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Histone Deacetylase Inhibitors; HIV Infections; HIV-1;

2021
Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV.
    Cell host & microbe, 2018, Jan-10, Volume: 23, Issue:1

    Topics: Anti-HIV Agents; Bryostatins; CD4-Positive T-Lymphocytes; Depsipeptides; HIV Infections; HIV-1; Huma

2018
Natural product-derived compounds in HIV suppression, remission, and eradication strategies.
    Antiviral research, 2018, Volume: 158

    Topics: Anti-HIV Agents; Biological Products; Bryostatins; Depsipeptides; Disease Reservoirs; Diterpenes; Dr

2018
The search for an HIV cure: tackling latent infection.
    The Lancet. Infectious diseases, 2013, Volume: 13, Issue:7

    Topics: Bone Marrow Transplantation; Enzyme Inhibitors; HIV Infections; Humans; Hydroxamic Acids; Virus Acti

2013
HDAC inhibitors in HIV.
    Immunology and cell biology, 2012, Volume: 90, Issue:1

    Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Clinical Trials as Topic; Histone Deacetylase Inhibitor

2012

Trials

7 trials available for vorinostat and HIV Coinfection

ArticleYear
Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 10-12, Volume: 75, Issue:8

    Topics: Acquired Immunodeficiency Syndrome; CD4-Positive T-Lymphocytes; DNA; Estrogen Receptor alpha; Female

2022
Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial.
    Lancet (London, England), 2020, 03-14, Volume: 395, Issue:10227

    Topics: Adult; AIDS Vaccines; Anti-Retroviral Agents; Disease Reservoirs; DNA, Viral; Histone Deacetylase In

2020
Participant Perspectives in an HIV Cure-Related Trial Conducted Exclusively in Women in the United States: Results from AIDS Clinical Trials Group 5366.
    AIDS research and human retroviruses, 2020, Volume: 36, Issue:4

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Patient Participation; Qualitative Research; Risk A

2020
Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial).
    Blood, 2020, 09-10, Volume: 136, Issue:11

    Topics: Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count;

2020
In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals.
    AIDS (London, England), 2019, 03-15, Volume: 33, Issue:4

    Topics: Histone Deacetylase Inhibitors; HIV Infections; Humans; Killer Cells, Natural; Panobinostat; Treatme

2019
In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals.
    AIDS (London, England), 2019, 03-15, Volume: 33, Issue:4

    Topics: Histone Deacetylase Inhibitors; HIV Infections; Humans; Killer Cells, Natural; Panobinostat; Treatme

2019
In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals.
    AIDS (London, England), 2019, 03-15, Volume: 33, Issue:4

    Topics: Histone Deacetylase Inhibitors; HIV Infections; Humans; Killer Cells, Natural; Panobinostat; Treatme

2019
In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals.
    AIDS (London, England), 2019, 03-15, Volume: 33, Issue:4

    Topics: Histone Deacetylase Inhibitors; HIV Infections; Humans; Killer Cells, Natural; Panobinostat; Treatme

2019
Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
    PLoS pathogens, 2014, Volume: 10, Issue:10

    Topics: Adult; CD4-Positive T-Lymphocytes; Female; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Hu

2014
Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
    PLoS pathogens, 2014, Volume: 10, Issue:10

    Topics: Adult; CD4-Positive T-Lymphocytes; Female; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Hu

2014
Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
    PLoS pathogens, 2014, Volume: 10, Issue:10

    Topics: Adult; CD4-Positive T-Lymphocytes; Female; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Hu

2014
Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
    PLoS pathogens, 2014, Volume: 10, Issue:10

    Topics: Adult; CD4-Positive T-Lymphocytes; Female; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Hu

2014
Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
    PLoS pathogens, 2014, Volume: 10, Issue:10

    Topics: Adult; CD4-Positive T-Lymphocytes; Female; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Hu

2014
Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
    PLoS pathogens, 2014, Volume: 10, Issue:10

    Topics: Adult; CD4-Positive T-Lymphocytes; Female; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Hu

2014
Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
    PLoS pathogens, 2014, Volume: 10, Issue:10

    Topics: Adult; CD4-Positive T-Lymphocytes; Female; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Hu

2014
Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
    PLoS pathogens, 2014, Volume: 10, Issue:10

    Topics: Adult; CD4-Positive T-Lymphocytes; Female; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Hu

2014
Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
    PLoS pathogens, 2014, Volume: 10, Issue:10

    Topics: Adult; CD4-Positive T-Lymphocytes; Female; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Hu

2014
Broad activation of latent HIV-1 in vivo.
    Nature communications, 2016, 09-08, Volume: 7

    Topics: Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; DNA, Viral; Drug Administration Schedule; HIV In

2016

Other Studies

41 other studies available for vorinostat and HIV Coinfection

ArticleYear
Study of marine natural products including resorcyclic acid lactones from Humicola fuscoatra that reactivate latent HIV-1 expression in an in vitro model of central memory CD4+ T cells.
    Journal of natural products, 2014, Mar-28, Volume: 77, Issue:3

    Topics: Ascomycota; Biological Products; CD4-Positive T-Lymphocytes; Histone Deacetylase Inhibitors; HIV Inf

2014
Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat.
    The Journal of infectious diseases, 2022, 03-02, Volume: 225, Issue:5

    Topics: Broadly Neutralizing Antibodies; CD4-Positive T-Lymphocytes; HIV Infections; HIV-1; Humans; Viremia;

2022
Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal.
    AIDS (London, England), 2022, 01-01, Volume: 36, Issue:1

    Topics: Disulfiram; Drug Therapy, Combination; HIV Infections; Humans; Virus Latency; Vorinostat

2022
Broadening community engagement in clinical research: Designing and assessing a pilot crowdsourcing project to obtain community feedback on an HIV clinical trial.
    Clinical trials (London, England), 2020, Volume: 17, Issue:3

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antibodies, Monoclonal; Clinical Trials as Topic; Clinical

2020
Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection.
    Scientific reports, 2020, 03-20, Volume: 10, Issue:1

    Topics: Adult; CD4-Positive T-Lymphocytes; Dendritic Cells; Histone Deacetylase Inhibitors; HIV Infections;

2020
4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat.
    Biochemical pharmacology, 2020, Volume: 177

    Topics: Anti-HIV Agents; Bryostatins; CD4-Positive T-Lymphocytes; Cell Survival; Drug Synergism; HIV Infecti

2020
Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat.
    Journal of virology, 2020, 06-16, Volume: 94, Issue:13

    Topics: Acetylation; CD4-Positive T-Lymphocytes; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Huma

2020
G-quadruplex ligands targeting telomeres do not inhibit HIV promoter activity and cooperate with latency reversing agents in killing latently infected cells.
    Cell cycle (Georgetown, Tex.), 2020, Volume: 19, Issue:18

    Topics: Acridines; Anti-HIV Agents; Apoptosis; Bryostatins; CD4-Positive T-Lymphocytes; DNA Damage; DNA Mism

2020
Myc matters in HIV-associated lymphoma.
    Blood, 2020, 09-10, Volume: 136, Issue:11

    Topics: HIV Infections; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Vorinostat

2020
Resveratrol Promotes HIV-1 Tat Accumulation via AKT/FOXO1 Signaling Axis and Potentiates Vorinostat to Antagonize HIV-1 Latency.
    Current HIV research, 2021, Volume: 19, Issue:3

    Topics: Anti-HIV Agents; HIV Infections; Humans; Proto-Oncogene Proteins c-akt; Resveratrol; Signal Transduc

2021
Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency.
    EBioMedicine, 2021, Volume: 65

    Topics: Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Cell Proliferation; Histone Deacetylase Inhibito

2021
The Myxobacterial Metabolite Soraphen A Inhibits HIV-1 by Reducing Virus Production and Altering Virion Composition.
    Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:8

    Topics: Acetyl-CoA Carboxylase; Anti-HIV Agents; Cell Line, Tumor; HIV Envelope Protein gp120; HIV Infection

2017
The histone deacetylase inhibitor SAHA simultaneously reactivates HIV-1 from latency and up-regulates NKG2D ligands sensitizing for natural killer cell cytotoxicity.
    Virology, 2017, Volume: 510

    Topics: Cells, Cultured; Gene Expression Profiling; GPI-Linked Proteins; Histocompatibility Antigens Class I

2017
Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency.
    The Journal of clinical investigation, 2017, Aug-01, Volume: 127, Issue:8

    Topics: Adult; Aged; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Drug Administration Schedule; Female; Hist

2017
Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells.
    EBioMedicine, 2017, Volume: 23

    Topics: Antigens, Viral; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-CD8 Ratio; CD8-Pos

2017
HIV latency is reversed by ACSS2-driven histone crotonylation.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Acetate-CoA Ligase; Animals; CD4-Positive T-Lymphocytes; Chromatin; Epigenesis, Genetic; Fatty Acids

2018
Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal
    Journal of virology, 2018, 06-15, Volume: 92, Issue:12

    Topics: Adult; Anti-Retroviral Agents; Antibody-Dependent Cell Cytotoxicity; CD4-Positive T-Lymphocytes; Cel

2018
Transcriptional Modulation of Human Endogenous Retroviruses in Primary CD4+ T Cells Following Vorinostat Treatment.
    Frontiers in immunology, 2018, Volume: 9

    Topics: Antirheumatic Agents; CD4-Positive T-Lymphocytes; Cells, Cultured; Endogenous Retroviruses; Gene Exp

2018
Mesenchymal stem cells are attracted to latent HIV-1-infected cells and enable virus reactivation via a non-canonical PI3K-NFκB signaling pathway.
    Scientific reports, 2018, 10-02, Volume: 8, Issue:1

    Topics: Anti-HIV Agents; Cell Line; Culture Media, Conditioned; Drug Evaluation, Preclinical; Gene Expressio

2018
An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients.
    PLoS pathogens, 2013, Volume: 9, Issue:12

    Topics: Acetamides; Adult; CD4-Positive T-Lymphocytes; Cells, Cultured; HEK293 Cells; Histone Deacetylase In

2013
Discovery of a small molecule agonist of phosphatidylinositol 3-kinase p110α that reactivates latent HIV-1.
    PloS one, 2014, Volume: 9, Issue:1

    Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line; Class Ia Phospha

2014
Short communication: SAHA (vorinostat) induces CDK9 Thr-186 (T-loop) phosphorylation in resting CD4+ T cells: implications for reactivation of latent HIV.
    AIDS research and human retroviruses, 2015, Volume: 31, Issue:1

    Topics: Acetaldehyde Dehydrogenase Inhibitors; CD4-Positive T-Lymphocytes; Cell Line; Cyclin T; Cyclin-Depen

2015
Activation of HIV-1 from latent infection via synergy of RUNX1 inhibitor Ro5-3335 and SAHA.
    PLoS pathogens, 2014, Volume: 10, Issue:3

    Topics: CCAAT-Binding Factor; Chromatin Immunoprecipitation; Core Binding Factor Alpha 2 Subunit; Drug Syner

2014
New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.
    Nature medicine, 2014, Volume: 20, Issue:4

    Topics: Anti-HIV Agents; Azepines; Bryostatins; CD4-Positive T-Lymphocytes; Cell Cycle Proteins; Depsipeptid

2014
Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy.
    Proceedings of the National Academy of Sciences of the United States of America, 2014, May-13, Volume: 111, Issue:19

    Topics: Adult; Aged; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Female; Gene Expression Regulation,

2014
Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy.
    Proceedings of the National Academy of Sciences of the United States of America, 2014, May-13, Volume: 111, Issue:19

    Topics: Adult; Aged; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Female; Gene Expression Regulation,

2014
Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy.
    Proceedings of the National Academy of Sciences of the United States of America, 2014, May-13, Volume: 111, Issue:19

    Topics: Adult; Aged; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Female; Gene Expression Regulation,

2014
Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy.
    Proceedings of the National Academy of Sciences of the United States of America, 2014, May-13, Volume: 111, Issue:19

    Topics: Adult; Aged; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Female; Gene Expression Regulation,

2014
Measuring reversal of HIV-1 latency ex vivo using cells from infected individuals.
    Proceedings of the National Academy of Sciences of the United States of America, 2014, May-13, Volume: 111, Issue:19

    Topics: Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Female; HIV Infections; HIV-1; Humans; Hydroxami

2014
The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events.
    Journal of virology, 2014, Volume: 88, Issue:18

    Topics: CD4-Positive T-Lymphocytes; Gene Expression Regulation, Viral; Histone Deacetylase Inhibitors; HIV I

2014
Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice.
    Cell, 2014, Aug-28, Volume: 158, Issue:5

    Topics: Animals; Anti-HIV Agents; Antibodies, Neutralizing; CD4-Positive T-Lymphocytes; CTLA-4 Antigen; Hete

2014
Ex vivo response to histone deacetylase (HDAC) inhibitors of the HIV long terminal repeat (LTR) derived from HIV-infected patients on antiretroviral therapy.
    PloS one, 2014, Volume: 9, Issue:11

    Topics: Adult; Aged; Anti-HIV Agents; Benzamides; Cell Line; HeLa Cells; Histone Deacetylase Inhibitors; HIV

2014
Experiences and expectations of participants completing an HIV cure focused clinical trial.
    AIDS (London, England), 2015, Jan-14, Volume: 29, Issue:2

    Topics: Clinical Trials as Topic; Data Collection; HIV Infections; Humans; Hydroxamic Acids; Patient Partici

2015
Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir.
    The Journal of infectious diseases, 2015, Jul-15, Volume: 212, Issue:2

    Topics: Anti-HIV Agents; Cells, Cultured; Coculture Techniques; HIV Infections; HIV-1; Humans; Hydroxamic Ac

2015
Short Communication: The Broad-Spectrum Histone Deacetylase Inhibitors Vorinostat and Panobinostat Activate Latent HIV in CD4(+) T Cells In Part Through Phosphorylation of the T-Loop of the CDK9 Subunit of P-TEFb.
    AIDS research and human retroviruses, 2016, Volume: 32, Issue:2

    Topics: Antiretroviral Therapy, Highly Active; Benzamides; CD4-Positive T-Lymphocytes; Cells, Cultured; Cycl

2016
Reactivation of Latent HIV-1 Expression by Engineered TALE Transcription Factors.
    PloS one, 2016, Volume: 11, Issue:3

    Topics: Activating Transcription Factors; CD4-Positive T-Lymphocytes; Cell Line; Gene Expression Regulation,

2016
Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation.
    Nature medicine, 2016, Volume: 22, Issue:7

    Topics: Acitretin; Adult; Aged; Anti-HIV Agents; Apoptosis; CD4-Positive T-Lymphocytes; DEAD Box Protein 58;

2016
The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function.
    Scientific reports, 2016, 08-02, Volume: 6

    Topics: Adult; CD4-Positive T-Lymphocytes; Cell Proliferation; Cytokines; Histone Deacetylase Inhibitors; HI

2016
No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy.
    AIDS (London, England), 2017, 05-15, Volume: 31, Issue:8

    Topics: Anti-Retroviral Agents; Antineoplastic Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Drug Interaction

2017
Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells.
    The Journal of biological chemistry, 2009, Mar-13, Volume: 284, Issue:11

    Topics: Adult; Antiretroviral Therapy, Highly Active; Female; HIV; HIV Infections; Humans; Hydroxamic Acids;

2009
Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells.
    The Journal of biological chemistry, 2009, Mar-13, Volume: 284, Issue:11

    Topics: Adult; Antiretroviral Therapy, Highly Active; Female; HIV; HIV Infections; Humans; Hydroxamic Acids;

2009
Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells.
    The Journal of biological chemistry, 2009, Mar-13, Volume: 284, Issue:11

    Topics: Adult; Antiretroviral Therapy, Highly Active; Female; HIV; HIV Infections; Humans; Hydroxamic Acids;

2009
Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells.
    The Journal of biological chemistry, 2009, Mar-13, Volume: 284, Issue:11

    Topics: Adult; Antiretroviral Therapy, Highly Active; Female; HIV; HIV Infections; Humans; Hydroxamic Acids;

2009
Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid.
    AIDS research and human retroviruses, 2009, Volume: 25, Issue:2

    Topics: CD4-Positive T-Lymphocytes; Cell Line; Cells, Cultured; Genes, Reporter; Green Fluorescent Proteins;

2009
Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid.
    AIDS research and human retroviruses, 2009, Volume: 25, Issue:2

    Topics: CD4-Positive T-Lymphocytes; Cell Line; Cells, Cultured; Genes, Reporter; Green Fluorescent Proteins;

2009
Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid.
    AIDS research and human retroviruses, 2009, Volume: 25, Issue:2

    Topics: CD4-Positive T-Lymphocytes; Cell Line; Cells, Cultured; Genes, Reporter; Green Fluorescent Proteins;

2009
Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid.
    AIDS research and human retroviruses, 2009, Volume: 25, Issue:2

    Topics: CD4-Positive T-Lymphocytes; Cell Line; Cells, Cultured; Genes, Reporter; Green Fluorescent Proteins;

2009
Scientists investigate routing latent HIV from its reservoirs to achieve a cure.
    JAMA, 2012, Jul-25, Volume: 308, Issue:4

    Topics: Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Clinical Trials as Topic; Histone Deacetylase In

2012
HIV: Shock and kill.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Anti-HIV Agents; HIV Infections; HIV-1; Humans; Hydroxamic Acids; Virus Latency; Vorinostat

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012